Medigene AG (PK) News - MDGEF

MediGene Initiates Clinical Phase I/II Trial of Cancer-Killing Virus NV1020 for the Treatment of Liver Metastases

MediGene Initiates Clinical Phase I/II Trial of Cancer-Killing Virus NV1020 for the Treatment of Liver Metastases MARTINSRIED, Germany and SAN...

3-Months Report: MediGene AG Reduces Net Loss by 84%

3-Months Report: MediGene AG Reduces Net Loss by 84% - Fivefold increase in revenues from 0.7 million euro to 3.9 million euro MARTINSRIED...

MediGene's First Drug Eligard(R) Is Launched

MediGene's First Drug Eligard(R) Is Launched * Marketing partner Yamanouchi launched cancer drug Eligard(R) in Germany today. MARTINSRIED, Germany...

MediGene Initiates Phase 2 Clinical Trial of Polyphenon(R) E Ointment for the Treatment of Actinic Keratosis on Schedule

MediGene Initiates Phase 2 Clinical Trial of Polyphenon(R) E Ointment for the Treatment of Actinic Keratosis on Schedule Expanding Market...

MediGene Decides on Extension of Clinical Development of Polyphenon(R) E Ointment to Additional Tumor Disease: Phase 2 Trial for

MediGene Decides on Extension of Clinical Development of Polyphenon(R) E Ointment to Additional Tumor Disease: Phase 2 Trial for Actinic Keratosis...

MediGene to Hold Conference Call to Discuss Excellent Clinical Results Of the Polyphenon(R) E Ointment European Phase 3 Trial

MediGene to Hold Conference Call to Discuss Excellent Clinical Results Of the Polyphenon(R) E Ointment European Phase 3 Trial MARTINSRIED...

MediGene Achieves Excellent Clinical Results With Polyphenon(R) E Ointment in European Phase 3 Trial

MediGene Achieves Excellent Clinical Results With Polyphenon(R) E Ointment in European Phase 3 Trial * Data indicate high and lasting efficacy as...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Medigene AG (PK) (MDGEF)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

MDGEF News

MediGene Initiates Clinical Phase I/II Trial of Cancer-Killing Virus NV1020 for the Treatment of Liver Metastases

3-Months Report: MediGene AG Reduces Net Loss by 84%

MediGene's First Drug Eligard(R) Is Launched

MediGene Initiates Phase 2 Clinical Trial of Polyphenon(R) E Ointment for the Treatment of Actinic Keratosis on Schedule

MediGene Decides on Extension of Clinical Development of Polyphenon(R) E Ointment to Additional Tumor Disease: Phase 2 Trial for

MediGene to Hold Conference Call to Discuss Excellent Clinical Results Of the Polyphenon(R) E Ointment European Phase 3 Trial

MediGene Achieves Excellent Clinical Results With Polyphenon(R) E Ointment in European Phase 3 Trial

MDGEF Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Medigene AG (PK) (MDGEF) News

Medigene AG (PK) (MDGEF)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

MDGEF News

MediGene Initiates Clinical Phase I/II Trial of Cancer-Killing Virus NV1020 for the Treatment of Liver Metastases

3-Months Report: MediGene AG Reduces Net Loss by 84%

MediGene's First Drug Eligard(R) Is Launched

MediGene Initiates Phase 2 Clinical Trial of Polyphenon(R) E Ointment for the Treatment of Actinic Keratosis on Schedule

MediGene Decides on Extension of Clinical Development of Polyphenon(R) E Ointment to Additional Tumor Disease: Phase 2 Trial for

MediGene to Hold Conference Call to Discuss Excellent Clinical Results Of the Polyphenon(R) E Ointment European Phase 3 Trial

MediGene Achieves Excellent Clinical Results With Polyphenon(R) E Ointment in European Phase 3 Trial

MDGEF Discussion

Your Recent History